NCT02604914View on ClinicalTrials.gov

A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

May 29, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions

Parkinson's Disease

Interventions

DRUG

ND0612

Subcutaneous solution

DRUG

LCIG

Intrajejunal Gel

Trial Locations (1)

NG11 6JS

Quotient Clinical LTD, Ruddington

Sponsors

Lead Sponsor

Collaborators (1)

Quotient Clinical

All Listed Sponsors

collaborator

Quotient Clinical

OTHER

lead

NeuroDerm Ltd.

INDUSTRY

NCT02604914 - A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects | Biotech Hunter | Biotech Hunter